Temasek Holdings’s Monte Rosa Therapeutics GLUE Stock Holding History

Temasek Holdings’s Portfolio GLUE Stock Details GLUE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$167K	Buy	+13,995	New	+$240K	﹤0.01%	188

Other funds holding GLUE

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Y-Intercept (HK) Hong Kong $4.52B AUM 6.6% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

Citigroup New York $308B AUM 40.94% 1-Year Est. Return

Profund Advisors Bethesda, Maryland $3.48B AUM 66.96% 1-Year Est. Return

Allspring Global Investments Charlotte, North Carolina $64.1B AUM 28.9% 1-Year Est. Return

AlphaCentric Advisors San Juan, Puerto Rico $113M AUM 27.37% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return

Creative Planning Overland Park, Kansas $179B AUM 16.96% 1-Year Est. Return

China Universal Asset Management Company Shanghai, China $1.92B AUM 74.14% 1-Year Est. Return

Temasek Holdings's GLUE Position: Q3 2026 in Review

Temasek Holdings opened a new position in Monte Rosa Therapeutics (GLUE) in Q3 2026: 13,995 shares worth $167K. The stake represents ﹤0.01% of the portfolio and ranks #188 among its holdings.

38 funds tracked by Wall St. Rank hold GLUE as of Q3 2026.

Temasek Holdings held 13,995 shares of Monte Rosa Therapeutics worth $167K as of Q3 2026.
Monte Rosa Therapeutics was a new Temasek Holdings position in Q3 2026.
Monte Rosa Therapeutics made up ﹤0.01% of Temasek Holdings's portfolio in Q3 2026, its #188 holding.
38 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q3 2026.

Based on Temasek Holdings's 13F filing for Q3 2026, filed 28 Oct 2026.